Matches in SemOpenAlex for { <https://semopenalex.org/work/W2131451331> ?p ?o ?g. }
- W2131451331 endingPage "685" @default.
- W2131451331 startingPage "678" @default.
- W2131451331 abstract "Background N-methyl-D-aspartate receptor (NMDAR)-mediated neurotransmission is vital for learning and memory. Hypofunction of NMDAR has been reported to play a role in the pathophysiology of Alzheimer disease (AD), particularly in the early phase. Enhancing NMDAR activation might be a novel treatment approach. One of the methods to enhance NMDAR activity is to raise the levels of NMDA coagonists by blocking their metabolism. This study examined the efficacy and safety of sodium benzoate, a D-amino acid oxidase inhibitor, for the treatment of amnestic mild cognitive impairment and mild AD. Methods We conducted a randomized, double-blind, placebo-controlled trial in four major medical centers in Taiwan. Sixty patients with amnestic mild cognitive impairment or mild AD were treated with 250–750 mg/day of sodium benzoate or placebo for 24 weeks. Alzheimer’s Disease Assessment Scale-cognitive subscale (the primary outcome) and global function (assessed by Clinician Interview Based Impression of Change plus Caregiver Input) were measured every 8 weeks. Additional cognition composite was measured at baseline and endpoint. Results Sodium benzoate produced a better improvement than placebo in Alzheimer’s Disease Assessment Scale-cognitive subscale (p = .0021, .0116, and .0031 at week 16, week 24, and endpoint, respectively), additional cognition composite (p = .007 at endpoint) and Clinician Interview Based Impression of Change plus Caregiver Input (p = .015, .016, and .012 at week 16, week 24, and endpoint, respectively). Sodium benzoate was well-tolerated without evident side-effects. Conclusions Sodium benzoate substantially improved cognitive and overall functions in patients with early-phase AD. The preliminary results show promise for D-amino acid oxidase inhibition as a novel approach for early dementing processes. N-methyl-D-aspartate receptor (NMDAR)-mediated neurotransmission is vital for learning and memory. Hypofunction of NMDAR has been reported to play a role in the pathophysiology of Alzheimer disease (AD), particularly in the early phase. Enhancing NMDAR activation might be a novel treatment approach. One of the methods to enhance NMDAR activity is to raise the levels of NMDA coagonists by blocking their metabolism. This study examined the efficacy and safety of sodium benzoate, a D-amino acid oxidase inhibitor, for the treatment of amnestic mild cognitive impairment and mild AD. We conducted a randomized, double-blind, placebo-controlled trial in four major medical centers in Taiwan. Sixty patients with amnestic mild cognitive impairment or mild AD were treated with 250–750 mg/day of sodium benzoate or placebo for 24 weeks. Alzheimer’s Disease Assessment Scale-cognitive subscale (the primary outcome) and global function (assessed by Clinician Interview Based Impression of Change plus Caregiver Input) were measured every 8 weeks. Additional cognition composite was measured at baseline and endpoint. Sodium benzoate produced a better improvement than placebo in Alzheimer’s Disease Assessment Scale-cognitive subscale (p = .0021, .0116, and .0031 at week 16, week 24, and endpoint, respectively), additional cognition composite (p = .007 at endpoint) and Clinician Interview Based Impression of Change plus Caregiver Input (p = .015, .016, and .012 at week 16, week 24, and endpoint, respectively). Sodium benzoate was well-tolerated without evident side-effects. Sodium benzoate substantially improved cognitive and overall functions in patients with early-phase AD. The preliminary results show promise for D-amino acid oxidase inhibition as a novel approach for early dementing processes." @default.
- W2131451331 created "2016-06-24" @default.
- W2131451331 creator A5006824926 @default.
- W2131451331 creator A5032031814 @default.
- W2131451331 creator A5036342199 @default.
- W2131451331 creator A5054571275 @default.
- W2131451331 creator A5058055584 @default.
- W2131451331 creator A5062121035 @default.
- W2131451331 creator A5070487411 @default.
- W2131451331 date "2014-05-01" @default.
- W2131451331 modified "2023-10-17" @default.
- W2131451331 title "Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled Trial" @default.
- W2131451331 cites W1164896577 @default.
- W2131451331 cites W1481130785 @default.
- W2131451331 cites W1556569805 @default.
- W2131451331 cites W1583957255 @default.
- W2131451331 cites W1589469155 @default.
- W2131451331 cites W1702894073 @default.
- W2131451331 cites W1847168837 @default.
- W2131451331 cites W1895538680 @default.
- W2131451331 cites W1930672392 @default.
- W2131451331 cites W1935267578 @default.
- W2131451331 cites W1941528024 @default.
- W2131451331 cites W1953027527 @default.
- W2131451331 cites W1959246743 @default.
- W2131451331 cites W1970826948 @default.
- W2131451331 cites W1975716424 @default.
- W2131451331 cites W1976741952 @default.
- W2131451331 cites W1982675433 @default.
- W2131451331 cites W1991444970 @default.
- W2131451331 cites W1991952617 @default.
- W2131451331 cites W2004097612 @default.
- W2131451331 cites W2006510420 @default.
- W2131451331 cites W2009190178 @default.
- W2131451331 cites W2017405704 @default.
- W2131451331 cites W2028384812 @default.
- W2131451331 cites W2029172258 @default.
- W2131451331 cites W2029932670 @default.
- W2131451331 cites W2030989440 @default.
- W2131451331 cites W2032444015 @default.
- W2131451331 cites W2039752037 @default.
- W2131451331 cites W2040402315 @default.
- W2131451331 cites W2042638856 @default.
- W2131451331 cites W2044397707 @default.
- W2131451331 cites W2049890856 @default.
- W2131451331 cites W2053687982 @default.
- W2131451331 cites W2054912209 @default.
- W2131451331 cites W2062355133 @default.
- W2131451331 cites W2062762429 @default.
- W2131451331 cites W2069655646 @default.
- W2131451331 cites W2078892755 @default.
- W2131451331 cites W2088710903 @default.
- W2131451331 cites W2091188240 @default.
- W2131451331 cites W2092356280 @default.
- W2131451331 cites W2093248761 @default.
- W2131451331 cites W2097293665 @default.
- W2131451331 cites W2097693778 @default.
- W2131451331 cites W2098644261 @default.
- W2131451331 cites W2101901330 @default.
- W2131451331 cites W2105376855 @default.
- W2131451331 cites W2106836101 @default.
- W2131451331 cites W2113996491 @default.
- W2131451331 cites W2116726454 @default.
- W2131451331 cites W2121683187 @default.
- W2131451331 cites W2126365703 @default.
- W2131451331 cites W2129497119 @default.
- W2131451331 cites W2141229271 @default.
- W2131451331 cites W2148000979 @default.
- W2131451331 cites W2151644670 @default.
- W2131451331 cites W2155039139 @default.
- W2131451331 cites W2156220037 @default.
- W2131451331 cites W216420585 @default.
- W2131451331 cites W2166982309 @default.
- W2131451331 cites W2169530911 @default.
- W2131451331 cites W2316145923 @default.
- W2131451331 cites W240821486 @default.
- W2131451331 cites W4211240111 @default.
- W2131451331 doi "https://doi.org/10.1016/j.biopsych.2013.08.010" @default.
- W2131451331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24074637" @default.
- W2131451331 hasPublicationYear "2014" @default.
- W2131451331 type Work @default.
- W2131451331 sameAs 2131451331 @default.
- W2131451331 citedByCount "105" @default.
- W2131451331 countsByYear W21314513312014 @default.
- W2131451331 countsByYear W21314513312015 @default.
- W2131451331 countsByYear W21314513312016 @default.
- W2131451331 countsByYear W21314513312017 @default.
- W2131451331 countsByYear W21314513312018 @default.
- W2131451331 countsByYear W21314513312019 @default.
- W2131451331 countsByYear W21314513312020 @default.
- W2131451331 countsByYear W21314513312021 @default.
- W2131451331 countsByYear W21314513312022 @default.
- W2131451331 countsByYear W21314513312023 @default.
- W2131451331 crossrefType "journal-article" @default.
- W2131451331 hasAuthorship W2131451331A5006824926 @default.
- W2131451331 hasAuthorship W2131451331A5032031814 @default.
- W2131451331 hasAuthorship W2131451331A5036342199 @default.
- W2131451331 hasAuthorship W2131451331A5054571275 @default.